周三，美国制药商 万达生物制药 宣布，其用于预防运动诱发性呕吐的药物已获得美国食品药品监督管理局(FDA)批准，成为40多年来首个获批的此类治疗药物。该公司预计将在未来几个月内推出这款名为Nereus的药物。
截至发稿，万达生物制药涨幅扩大至35%。
周三，美国制药商 万达生物制药 宣布，其用于预防运动诱发性呕吐的药物已获得美国食品药品监督管理局(FDA)批准，成为40多年来首个获批的此类治疗药物。该公司预计将在未来几个月内推出这款名为Nereus的药物。
截至发稿，万达生物制药涨幅扩大至35%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
